Ignite Creation Date:
2024-05-05 @ 5:04 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00373646
Status:
COMPLETED
Last Update Posted:
2009-06-18
First Post:
2006-09-07
Brief Title:
Thalidomide in Mucosa Associated Lymphoid Tissue MALT Lymphoma Patients
Sponsor:
Medical University of Vienna
Organization:
Medical University of Vienna
Study Overview
Official Title:
Phase II Trial of Thalidomide Thalidomide Pharmion in Patients With Advanced or Relapsed Lymphoma of the Mucosa Associated Lymphoid Tissue MALT
Status:
COMPLETED
Status Verified Date:
2009-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate Thalidomide for treatment of disseminated MALT Lymphoma or at relapse following helicobacter pylori HP - eradication or chemotherapy or radiation
Detailed Description:
The objectives of this study are to evaluate the effectivity and the safety of thalidomide in patients with disseminated MALT lymphoma or at relapse following HP-eradication or chemotherapy or radiation It is a phase II prospective single arm study with a target sample size of 16 patients Thalidomide is given orally at an initial dose of 100 mg for a maximum duration of 6 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Eudract number 2005-000008-14 | None | None | None |